Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study-Reference-Cited by-同舟云学术

Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study

Published:2020-04 Issue:4 Volume:77 Page:494-500
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Matsubara Nobuaki,Chi Kim N.,Özgüroğlu Mustafa,Rodriguez-Antolin Alfredo,Feyerabend Susan,Fein Luis,Alekseev Boris Y.,Sulur Giri,Protheroe Andrew,Li Susan,Mundle Suneel,De Porre Peter,Tran Namphuong,Fizazi Karim

Publisher

Elsevier BV

Subject

Urology

Reference28 articles.

1. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide;Hassanipour-Azgomi;Prostate Int,2016

2. Increasing incidence of metastatic prostate cancer in the United States (2004–2013);Weiner;Prostate Cancer Prostatic Dis,2016

3. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy;Cooperberg;J Clin Oncol,2009

4. Prostate cancer in Asian men;Ito;Nat Rev Urol,2014

5. Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019);James;Eur Urol,2015

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05);Practical Radiation Oncology;2024-09

2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer;European Urology;2024-08

3. Survival Patterns Based on First-site–specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?;European Urology Open Science;2024-08

4. Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis;European Urology Oncology;2024-08

5. Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?;Cancers;2024-06-26